Immunology / Virology & Vaccines

Covid-19
#Biotechnology #Covid-19 #Immunology / Virology & Vaccines

Developing next generation pan-SARS-CoV-2 vaccines 

SpyBiotech, a UK-based biotechnology company with a novel vaccine platform technology that can target infectious diseases, cancer, and chronic diseases, has received a grant of $4,094,561 from the Bill & Melinda Gates Foundation to further develop its novel SpyVector platform.   This project will harness SpyBio’s ‘plug… Read More

#Covid-19 #News

T cell attacking Covid-19
#Covid-19 #Covid-19 vaccine #Immune response #Immunology / Virology & Vaccines #SARS-CoV-2 #T cell activation

Covid-19 causes long-term damage to the immune system

New findings suggest that the SARS-CoV-2 virus damages an important immune-cell response. The quality of CD8+ T cell response to two doses of the Pfizer-BioNTech Covid-19 vaccine was considerably lower in people with prior SARS-CoV-2 infection compared to people without prior infection, the US study found. Read More

#News #Trending News

#Drug development #Drug discovery #eBook #Immunology / Virology & Vaccines #mRNA #mRNA-based vaccines

eBook: mRNA development, manufacturing, and beyond

A new eBook is now available entitled ‘Riding the mRNA highway: development, manufacturing, and beyond’, sponsored by Thermo Fisher Scientific. Download the eBook to learn more about process development and manufacturing in the mRNA space to enable successful scale-ups of mRNA production for therapeutic applications. Topics covered… Read More

#News

#Drug development #Drug discovery #Immunology / Virology & Vaccines #mRNA #mRNA-based vaccines

Riding the mRNA highway: development, manufacturing, and beyond

Download this eBook to learn more about process development and manufacturing in the mRNA space to enable successful scale-ups of mRNA production for therapeutic applications. Topics covered in the eBook include: Expert views on mRNA development and manufacturing Advantages of mRNA processes compared to traditional vaccine manufacturing Best practices for… Read More

#Resources

Genetically engineering virus in the lab
#Bacteria #Genetic editing #Genetic engineering #Harvard Medical School #Immunology / Virology & Vaccines #RNA

Scientists engineer safe, virus-resistant E coli for research

In a step forward for genetic engineering and synthetic biology, US researchers have modified E coli bacteria to be immune to infection by all natural viruses tested so far. The team used two safeguard methods to prevent the bacteria and their modified genes from escaping into… Read More

#Editor's Choice #News

Monocyte
#Covid-19 #Immune cells #Immune response #Immunology / Virology & Vaccines #Long Covid

Malfunctioning monocytes could be drug target in long Covid

Researchers have shown for the first time that malfunctioning behaviour of a type of immune cell is linked to specific symptoms of long Covid. Normally functioning monocytes, made in the bone marrow, would travel through the blood to the lungs where they surround and kill the… Read More

#Editor's Choice #News

Scotland
#Gilead Sciences #hepatitis #Immunology / Virology & Vaccines #Marketing approval authorisation #Scottish Medicines Consortium (SMC)

Scottish regulator approves first chronic hepatitis delta virus drug

The Scottish Medicines Consortium (SMC) has become the first UK health authority to permit routine NHS use of Gilead Sciences’ Hepcludex (bulevirtide) for the treatment of chronic hepatitis delta virus (HDV) infection. The drug has been accepted for the treatment of chronic HDV infection in adult patients with evidence of… Read More

#News #Regulatory

#Drug development #High throughput screening #Immunology / Virology & Vaccines #IVT #mRNA #RNA #Thermo Fisher Scientific

New listicle: Five tips on scaling up IVT for mRNA production

The success of messenger RNA or mRNA vaccines in the fight against the global SARS-CoV-2 crisis brings a new era of vaccine development. In vitro transcription, or IVT, is a complex reaction, requiring key components like an RNA polymerase, nucleotides, and a DNA template to make each mRNA. By partnering… Read More

#Editor's Choice #News

#Drug development #High throughput screening #Immunology / Virology & Vaccines #IVT #mRNA #RNA #Thermo Fisher Scientific

Listicle: Five tips on scaling up IVT for mRNA production

In this listicle, Thermo Fisher Scientific outlines five measures to help you ensure consistency in your workflow and produce reproducible, high-quality batches of IVT mRNA at scale. The success of messenger RNA (mRNA) vaccines in combatting the global SARS-CoV-2 crisis brings a new era of vaccine development. Read More

#Listicles #Videos

Dr Edo Kon
#Antibiotic resistance #Antimicrobial resistance (AMR) #Bacteria #Immunology / Virology & Vaccines #mRNA #mRNA-based vaccines

mRNA vaccine 100% effective against deadly bacteria

For the first time, researchers have developed an mRNA vaccine that is 100% effective against a type of bacteria that is lethal to humans, paving the way for effective vaccination against antibiotic-resistant bacteria. The study, conducted in an animal model, demonstrated that all treated animals were… Read More

#News #Trending News

#Immunology / Virology & Vaccines #mRNA #mRNA-based vaccines #Rare disease #Rare Disease Day #Thermo Fisher Scientific

Unlocking the potential of mRNA for the future treatment of rare diseases 

mRNA technology helped us to vaccinate the world against SARS-CoV-2. As we turn our focus to new potential applications and disease areas for the platform, scientists and companies must consider the potential life-saving impact on rare, inherited diseases, says Archana Gupta, PhD, staff scientist in genetic sciences at Thermo Fisher… Read More

#Exclusive Content #Opinion

#Covid-19 #Drug development #Drug discovery #HIV #Immunity #Immunology / Virology & Vaccines #Vaccines

New episode of the DDW Highlights podcast

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  Our news highlights this week focus on research into vaccines, with… Read More

#News

#Covid-19 #Drug development #Drug discovery #HIV #Immunity #Immunology / Virology & Vaccines #Vaccines

This week in drug discovery (20-24 February)

News round-up for 20-24 February by DDW Digital Content Editor Diana Spencer.  Our news highlights this week focus on research into vaccines, with good news for the treatment or prevention of various challenging conditions, including Covid-19, Strep A and HIV. Particularly interesting is the announcement that a new class… Read More

#News

Vaccine
#AELIX Therapeutics #HIV #Immune response #Immunology / Virology & Vaccines #Phase II trial #T cell activation

HIV combination regimen could lead to viral remission

AELIX Therapeutics has announced positive results from its randomised, placebo-controlled Phase IIa therapeutic HIV vaccine and immune modulator combination clinical trial.  The AELIX-003 trial evaluated the safety, tolerability, immunogenicity and efficacy of AELIX’s HTI T-cell therapeutic HIV vaccine in combination with Gilead’s investigational Toll-Like Receptor 7 (TLR7)… Read More

#News #Trending News

Vaccine
#Covid booster #Covid-19 #Immunology / Virology & Vaccines #Phase III trial #Vaxxinity

New Covid-19 booster outperforms approved vaccines

Covid-19 booster candidate UB-612 has achieved its immunogenicity endpoints in a head-to-head trial against three vaccine platforms: mRNA (Pfizer-BioNTech’s BNT162b2), adenovirus vector (AstraZeneca’s ChAdOx1-S), and inactivated virus (Sinopharm’s BIBP).  The results show UB-612 elicits superior neutralising antibody titers and seroconversion rates against… Read More

#News #Trending News

Doctor vaccinating baby
#FDA #Immunology / Virology & Vaccines #Paediatric #Phase II trial #Pneumonia

Pneumococcal vaccine gets go-ahead for infant trial

The US Food and Drug Administration (FDA) has cleared Vaxcyte’s infant Investigational New Drug (IND) application for VAX-24, its 24-valent pneumococcal conjugate vaccine (PCV) candidate designed to prevent invasive pneumococcal disease (IPD).  The company plans to initiate the infant Phase II study in the second… Read More

#News